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Abstract
Alzheimer’s disease (AD) is a conformational disease that is characterized by amyloid-b (Ab) deposition in the brain. Ab
exerts its toxicity in part by receptor-mediated interactions that cause down-stream protein misfolding and aggregation, as
well as mitochondrial dysfunction. Recent reports indicate that Ab may also interact directly with intracellular proteins such
as the mitochondrial enzyme ABAD (Ab binding alcohol dehydrogenase) in executing its toxic effects. Mitochondrial
dysfunction occurs early in AD, and Ab’s toxicity is in part mediated by inhibition of ABAD as shown previously with an
ABAD decoy peptide. Here, we employed AG18051, a novel small ABAD-specific compound inhibitor, to investigate the role
of ABAD in Ab toxicity. Using SH-SY5Y neuroblastoma cells, we found that AG18051 partially blocked the Ab-ABAD
interaction in a pull-down assay while it also prevented the Ab42-induced down-regulation of ABAD activity, as measured
by levels of estradiol, a known hormone and product of ABAD activity. Furthermore, AG18051 is protective against Ab42
toxicity, as measured by LDH release and MTT absorbance. Specifically, AG18051 reduced Ab42-induced impairment of
mitochondrial respiration and oxidative stress as shown by reduced ROS (reactive oxygen species) levels. Guided by our
previous finding of shared aspects of the toxicity of Ab and human amylin (HA), with the latter forming aggregates in Type 2
diabetes mellitus (T2DM) pancreas, we determined whether AG18051 would also confer protection from HA toxicity. We
found that the inhibitor conferred only partial protection from HA toxicity indicating distinct pathomechanisms of the two
amyloidogenic agents. Taken together, our results present the inhibition of ABAD by compounds such as AG18051 as a
promising therapeutic strategy for the prevention and treatment of AD, and suggest levels of estradiol as a suitable read-
out.
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Introduction
In the Alzheimer’s disease (AD) brain, amyloid-b (Ab) has a
central yet only partly understood role in the neurodegenerative
process [1]. Apart from constituting the amyloid plaque as a
classical hallmark lesion of AD, Ab acts via a plethora of pathways
to induce synaptic and neuronal degeneration [2–4]. Many studies
reveal that in exerting its toxicity, Ab binds to specific receptors
and/or lipids at the neuronal cell membrane, and some studies
even suggest a disruption of ion homeostasis by forming channels
or pores [5,6]. To better understand what the prerequisites are for
Ab toxicity, we and others used transgenic mouse models and
found that Ab mediates its toxicity in part through the NMDA
receptor, with an essential role for the microtubule-associated
protein tau [7–9], that similar to Ab, also forms insoluble
aggregates in the AD brain. Over-activation of the NMDA
receptor complex results in excessive nitric oxide (NO) levels,
causing down-stream protein misfolding and aggregation, as well
as mitochondrial dysfunction. The toxic signaling pathway further
involves the release of mitochondrial cytochrome c and the
activation of down-stream caspases as well as the formation of
ROS (reactive oxygen species) [10–12], highlighting mitochondria
as a prime down-stream target of Ab [13–15].
Interestingly, mitochondria represent not only an indirect
target; instead, in several studies Ab has been localized to [16]
and shown to act directly on mitochondria [17,18] whose function
it impairs [19–22]. Among the mitochondrial proteins to which Ab
has been shown to bind is the enzyme amyloid-binding alcohol
dehydrogenase (ABAD) [23,24]. ABAD interacts with Ab and is a
major determinant of Ab toxicity [17,25,26]. Specifically, in mice
doubly transgenic for ABAD and the Ab-precursor APP, the toxic
effects of Ab are aggravated compared to what is found in APP
single transgenic mice [17].
ABAD is the Type 10 member of a protein family, known as
17b-hydroxysteroid dehydrogenases (HSD17B) [27]. The enzyme
is found in mitochondria, while the other known fourteen family
members are confined to the endoplasmic reticulum (ER) sug-
gesting that ABAD has a specialized function within mitochondria
[28]. ABAD converts estradiol to estrone [29], and its levels are
critical as optimal estradiol levels are an important determinant of
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neuronal survival [29]. In post-menopausal women, the estrogen
replacement therapy has been shown to delay the onset of AD
[30]. In the placenta and in ovaries, ABAD inactivates estradiol by
oxidizing it to estrone [31,32], and this may also occurs in testis
[33]. Interestingly, ABAD levels themselves are sensitive to
estradiol levels suggesting a feedback loop in the regulation of its
activity [34].
The many reports of ABAD’s enzymatic action on various
substrates in vivo have been challenged, however, by strong evidence
that a catalytically inactive mutant of ABAD as identified in a young
boy had no ill effects on his health [35]. In addition, ABAD was
found to be one of only three proteins that comprise the fully
functional mammalianmitochondrial RNAse P [36], a function that
may not require enzymatic activity and that links ABAD directly to
the production of mitochondrial electron transport chain proteins
and reactive oxygen species (ROS) generation [37].
Binding of Ab to ABAD induces a conformational change that
is inhibited by NAD+ (nicotinamide adenine dinucleotide), with
binding of Ab and NAD+ being mutually exclusive [38]. Ab
binding results in the loss of ABAD function and ultimately,
neuronal apoptosis [39,40]. To directly determine whether Ab-
induced toxicity is mediated by ABAD inhibition and to establish
estradiol levels as a suitable readout, we here employed the use of
AG18051, a novel ABAD inhibitor [41].
Materials and Methods
Cell culture and incubation with amyloid peptides
SH-SY5Y neuroblastoma cells (DSMZ, Braunschweig, Ger-
many; DSMZ No. ACC 209) were grown in Dulbecco’s Modified
Eagle Medium: F-12 (DMEM: F-12) supplemented with 2 mM
L-glutamine, 1% penicillin/streptomycin and 10% fetal bovine
serum (FBS) (GIBCO, Basel, Switzerland) [42,43]. Ab42, human
amylin (HA), biotinylated Ab42 and biotinylated HA were
purchased from Bachem (Germany) (H-1368, H-7905, H-5642
and 3004028, respectively). The negative control, biotin, was
purchased from Sigma (B4639). Biotinylated and unmodified
Ab42 were dissolved in DMSO to make stocks of 5 mM and
stored at 280uC until use. Biotinylated and unmodified HA were
dissolved in 0.01 M acetic acid (AA) to make stocks of 5 mM and
also stored at 280uC until use. Biotin was dissolved in DMSO to
make stocks of 5 mM and kept at 280uC until use. Aging of the
peptides was induced by shaking at 1000 rpm for 4 days at 37uC.
0.5 mM Ab42 or human amylin (HA) was used for all experiments
in this study, while the treatment duration was always 5 days.
Pre-treatment experiments were performed by incubating
SH-SY5Y cells with 0.05 mM AG18051 for 24 hours, washing 3
times with warm PBS, and then treating the cells with 0.5 mM
Ab42 or HA for 5 days. Co-treatment experiments were done by
incubating SH-SY5Y cells for 5 days with 0.05 mM AG18051 and
0.5 mM Ab42 or HA, respectively.
LDH and MTT assays
LDH and MTT assays were chosen to provide indications for
cell viability after treatments. Assays were obtained from Roche
and were performed according to the manufacturer’s protocols.
Briefly, cells were exposed to the various treatments, after which
the medium was retrieved for LDH analysis, while the remaining
cells were washed 3 times with sterile PBS and the MTT assay
performed with the cells.
Pull-down assay
SH-SY5Y cells were grown to 70% confluency and treated
with vehicle, biotinylated Ab42, biotinylated HA, or biotin,
respectively, at a final concentration of 0.5 mM for 5 days. In
addition, 0.5 mM biotin and 0.5 mM biotinylated Ab42, respec-
tively, was co-incubated with 0.05 mM AG18051 for 5 days. After
5 days, cells were once washed with pre-warmed PBS and
immediately scraped with 500 mL ice-cold IP buffer (10 mM Tris,
0.1 M NaCl, 1 mM EDTA), supplemented with the Complete
EDTA-free protease inhibitor cocktail (1:25) (Roche, Basel,
Switzerland), and spun at 14 0006 g for 10 minutes at 4uC.
20 ml of magnetic Dynabeads MyOneTM Streptavidin T1
(Invitrogen) were added to each tube and tubes were rotated for
30 minutes at room temperature. Beads were subsequently washed
3 times with 16 PBS, followed by boiling in loading buffer
containing b-mercaptoethanol at 95uC for 5 minutes at 1000 rpm
to release bound peptides. Samples were then briefly spun down at
room temperature and supernatants loaded onto 12% glycine gels
for electrophoresis and Western blotting.
Quantification of estradiol as a functional read-out of
ABAD activity
After treatment with amyloid peptides and controls, the cell
culture medium was collected and cells were resuspended in cell
lysis buffer consisting of 150 mM Tris HCl, 150 mM NaCl, 1%
NP-40, 0.1% SDS, 2 mM EDTA and Complete protease inhibitor
(1:50) (Roche Diagnostics). The estradiol assay was performed
according to the manufacturer’s guidelines (Estradiol EIA Kit,
Cayman). In brief, the plate was loaded with samples, along with
the estradiol tracer and the specific antiserum to estradiol and
incubated for one hour at room temperature. After five washing
steps, Ellman’s Reagent was added and the plate developed for
60 minutes with gentle shaking at room temperature. The
calculated estradiol concentration was normalized to the total
protein content of the samples.
Figure 1. Ab42 binds to and impairs ABAD activity, while HA
(human amylin) does not. (A) Treatment of SH-SY5Y human
neuroblastoma cells with Ab42 causes decreased levels of estradiol,
indicative of an impairment of ABAD activity, while HA does not. Results
are means 6 SE, (n = 5 to 6 per group), **, P,0.01 (B) Pull-down of
ABAD from SH-SY5Y cells shows that different from HA, Ab42 can bind
to ABAD in vitro. (C) Structure of the ABAD inhibitor, AG18051 (adapted
from Kissinger et al., JMB 2004).
doi:10.1371/journal.pone.0028887.g001
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Mitochondrial respiration in vital cells
After treatment with amyloid peptides and controls, mito-
chondrial oxygen consumption was measured at 37uC using an
Oroboros Oxygraph-2k system. Five million cells were added to
2 ml of a mitochondrial respiration medium containing
0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate,
20 mM taurine, 10 mM KH2P04, 20 mM HEPES, 110 mM
sucrose and 1 g/l BSA (pH 7.1). To measure the state 4
respiration of complex I, 5 mM pyruvate and 2 mM malate
were added and cells permeabilised with 15 mg/ml digitonin.
Afterwards, 2 mM ADP was added to measure state 3
respiration. The integrity of the mitochondrial membrane was
checked by the addition of 10 mM cytochrome c. After
determining coupled respiration, 0.4 mM FCCP (Carbonyl
cyanide p-(trifluoro-methoxy) phenyl-hydrazone) was added
and respiration was measured in the absence of a proton
gradient. To inhibit complex I activity, 0.5 mM rotenone was
added.
Determining ROS levels
Levels of ROS were measured using different fluorescent probes
that allow detection at different cellular sites. The non-fluorescent
probe 29,79-dichlorodihydrofluorescein diacetate (H2DCF-DA)
was used to measure cytosolic ROS, most notably hydrogen
peroxide [44]. To determine levels of superoxide anion radicals,
DHE was used, which is oxidized to the fluorescent ethidium
cation by O2.2 [22]. For detection of mitochondria-associated
ROS we used the probe dihydrorhodamine (DHR), which
localizes to mitochondria and when oxidized by ROS, particularly
peroxinitrite, fluoresces to the positively charged rhodamine 123
derivate. Treated cells (Ab42, HA, and vehicle) were loaded with
10 mM H2DCF-DA, 10 mM DHR or 10 mM DHE, respectively,
for 15 min. After washing twice with Hank’s balanced salt (HBS)
solution, the formation of fluorescent products was measured by
detecting the emitted fluorescent units per 56105 cells using the
Fluoraskan Ascent FL multiplate reader (Labsystems, Helsinki,
Finland) (i) at 485 nm (excitation)/538 nm (emission) for both
Figure 2. Effects of the ABAD inhibitor AG18051 on cell viability and estradiol levels. (A) LDH assay of SH-SY5Y human neuroblastoma
cells incubated with increasing concentrations of AG18051 (normalized to 1 for control) shows that the ABAD inhibitor is not toxic at concentrations
of 0.1 mM and below. (B) Treatment of SH-SY5Y cells with increasing concentrations of AG18051 causes reduced levels of estradiol. *, P,0.05.
doi:10.1371/journal.pone.0028887.g002
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dichlorofluorescein (DCF) generated from H2DCF-DA via
oxidation, and DHR, and (ii) at 530 nm (excitation)/590 nm
(emission) for DHE, as previously described [45].
Results
Ab42 binds to and down-regulates ABAD activity,
different from human amylin
Ab exerts its toxicity in part by impairing ABAD [17], an
enzyme known to convert estrone to estradiol. To determine the
toxicity of the major fibrillogenic form of Ab and the role ABAD
has in this process, we incubated human SH-SY5Y neuroblastoma
cells for 5 days with Ab42, followed by measuring estradiol levels
in the cell lysate. We found that its levels were significantly
decreased after Ab42 exposure (p,0.0001) (Fig. 1A). To
determine if the deregulation of ABAD activity is a common
phenomenon shared by Ab with other amyloidogenic proteins, we
treated the cells also with human amylin (HA), a protein twice the
size of Ab and known to form aggregates in another disease with
protein aggregation, Type 2 diabetes mellitus (T2DM). However,
Figure 3. The Ab-mediated decrease in estradiol levels is prevented by AG18051. (A) Scheme of pre- and co-incubation treatment. (B) Pre-
treatment of cells with AG18051 for 24 hours prior to adding Ab42 maintains estradiol levels compared to the vehicle control, (C) as does co-
treatment. **, P,0.01.
doi:10.1371/journal.pone.0028887.g003
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different from Ab42, HA did not cause reductions in estradiol
levels (p,0.0001) (Fig. 1A).
Data obtained by x-ray crystallography of Ab42-ABAD
complexes indicate that it may be the direct association of Ab42
and ABAD that inhibits ABAD activity, as an association of Ab
with ABAD prevents it from binding to its physiological sub-
strate, NAD+ [17]. Since HA, different from Ab42, did not
down-regulate ABAD activity as measured by estradiol levels, and
as it is known that Ab42 is capable of inhibiting ABAD activity by
direct interaction [38], we sought to determine whether HA,
similar to Ab, would interact with ABAD. Therefore, SH-SY5Y
cells were incubated with 0.5 mM biotinylated Ab42 (BAb),
biotinylated HA (BHA), biotin or vehicle for 5 days. We found
by pull-down that while biotinylated Ab42 was bound to ABAD,
biotinylated HA, along with the negative control, was not (Fig. 1B).
Together with the estradiol activity assay, this suggests that the
reductions in estradiol levels caused by Ab42 may be mediated by
a direct interaction of Ab with ABAD.
The ABAD inhibitor AG18051 causes reduced estradiol
levels
To better understand the effect of Ab on estradiol levels we used
AG18051, a small molecule inhibitor of ABAD with high affinity
[41,46] (Fig. 1C). AG18051 exerts its inhibitory effect by
occupying the substrate-binding site of ABAD, which results in
the formation of a covalent adduct with the NAD+ cofactor. As the
interaction of ABAD with NAD+ is necessary for its activity,
disrupting ABAD/NAD+ complex formation obliterates ABAD
activity, resulting in decreased estradiol levels. We first determined
the toxicity profile of AG18051 in our SH-SY5Y cell culture
system. Concentrations of AG18051 up to 0.1 mM were not
overtly toxic and therefore, concentrations within the 0.05–
0.1 mM range were chosen for subsequent studies (Fig. 2A). The
toxicity at higher concentrations argues for a proper dosing. The
concentration range applied by us is consistent with the IC50
determined for AG18051 in a previous study [47,48]. With
increasing concentrations of the inhibitor, as expected, estradiol
levels were reduced (Fig. 2B). At 0.05 mM however, there was a
slight, but non-significant increase in estradiol levels suggesting
compensatory mechanisms.
AG18051 prevents Ab42-induced reductions in estradiol
levels
To determine whether AG18051 has an effect on the Ab42-
induced reduction of estradiol levels (Fig. 1A) and whether the
putative neuroprotective effect is via a ‘priming effect’ of the cells,
we both pre- and co-incubated SH-SY5Y cells with Ab42 and
0.05–0.1 mM AG18051 as outlined in the scheme (Fig. 3A). For
both treatment conditions, we found that this maintained estradiol
levels in the lysate, compared to a significant reduction in the
Ab42-only treatment (Fig. 3B,C). This suggests that AG18051 is
neuroprotective, and that it may exert its neuroprotective effect
either by priming cells to become resistant to the effects of Ab42,
or via a direct inhibition of the Ab42-ABAD interaction as
previously suggested [41].
AG18051 partially prevents ABAD-Ab42 interaction
To determine whether AG18051 treatment reverses the Ab42-
induced toxicity because AG18051 directly blocks the physical
interaction between Ab42 and ABAD, SH-SY5Y cells were
treated with 0.5 mM of biotinylated Ab42 (BAb) in the presence of
0.05 mM AG18051. We found that co-incubation of AG18051
significantly decreased the amount of ABAD pulled down by
biotinylated Ab42 (BAb) (Fig. 4). This suggests that AG18051
may prevent Ab42 toxicity by directly inhibiting the associ-
ation of Ab42 with ABAD. In addition, this also suggests that
AG18051 may exert its neuroprotective effects via additional
pathways other than a direct inhibition of the Ab42-ABAD
interaction.
Ab42-mediated reduction in cell viability prevented by
ABAD inhibitor AG18051
Having determined 0.05–0.1 mM as a suitable concentration
range for AG18051, we tested its putative neuroprotective effect in
Ab42 toxicity. SH-SY5Y cells were incubated with 0.5 mM Ab42
with or without AG18051, and toxicity was determined as
increased levels of LDH compared to vehicle control. Co-
incubation of Ab42 with either 0.05 or 0.1 mM AG18051,
respectively, resulted in a significant decrease in LDH levels back
to control levels (Fig. 5A). This indicates that inhibiting ABAD
activity protects from Ab toxicity.
We next investigated the effect of Ab on metabolic functions
and found that besides significantly increasing LDH levels, 0.5 mM
Ab42 also caused a significant decrease in MTT absorbance,
suggesting impaired metabolic functions caused by this amyloido-
genic peptide (Fig. 5B). Co-incubation of Ab42 with either 0.05 or
0.1 mM AG18051, respectively, resulted in a smaller decrease of
MTT absorbance (Fig. 5B,C). Since MTT measurements are an
indicator of mitochondrial health, the results suggest that Ab42
induces cell toxicity, as reflected by LDH levels, at least in parts via
impaired mitochondrial functions, with inhibition of the mito-
chondrial enzyme ABAD providing partial protection.
Figure 4. Pull-down of ABAD from SH-SY5Y cells shows that
different from HA, Ab42 can bind to ABAD in vitro. The presence
of AG18051 significantly decreases the amount of ABAD pulled down
by biotinylated Ab42 (BAb). *, p,0.05.
doi:10.1371/journal.pone.0028887.g004
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AG18051 restored Ab42-induced deficits on oxidative
phosphorylation (OXPHOS) capacity
To investigate the protective effect of AG18051 against Ab42
toxicity at the mitochondrial level, we used a high-resolution
respiratory protocol that we have established previously [49].
Specifically, physiological substrate combinations were used to
investigate mitochondrial function in SH-SY5Y cells (Fig. 6). We
compared OXPHOS, i.e. the entire electron transport system
(ETS) that is composed of the four mitochondrial enzymes
(complex I–IV) and the F1F0ATP synthase, in cells treated with
either vehicle, Ab42, AG18051, as well as in cells that were pre-
treated with AG18051 followed by exposure to Ab42 (see scheme,
Fig. 3A). We used the NADH generating substrates pyruvate and
malate to determine state 4 respiration (Fig. 6). State 3 respiration
measures the capacity of mitochondria to metabolize oxygen and
the selected substrate in the presence of a defined amount of ADP,
which is a substrate for the ATP synthase (complex V). State 4
respiration represents a ‘‘basal-coupled’’ rate of respiratory chain
activity and reflects activities of respiratory chain complexes and
proton leakage across the inner mitochondrial membrane. We
observed significantly reduced state 3 and state 4 respirations in
Ab42-treated cells (Fig. 6). After uncoupling with FCCP, the
respiratory rate increased in the absence of a proton gradient,
which indicates the maximum capacity of electron transport chain.
This maximum OXPHOS capacity was again significantly
impaired in Ab42-treated (Fig. 6).
Of note, AG18051 was able to significantly ameliorate the
Ab42-induced global failure of mitochondrial respiration, but by
Figure 5. The ABAD inhibitor AG18051 prevents the toxicity and metabolic impairment caused by Ab. (A) Co-incubation of AG18051
and Ab42 maintains the Ab42-induced change in LDH levels at baseline levels. (B) The metabolic impairment as determined with the MTT assay is also
prevented by co-incubation of Ab42 with AG18051. (C) Pre-incubation of the cells with AG18051 for 24 hours prior to adding Ab42 is similarly
protective to Ab’s toxicity as measured with the MTT assay. *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0028887.g005
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itself had no effect per se on oxygen consumption attaining levels
comparable to vehicle treatment (Fig. 6).
AG18051 prevents the increase in ROS levels caused by
Ab42
Increased ROS levels have been implicated in AD [50,51]. We
had previously found that treatment of SH-SY5Y cells with Ab42
caused significantly increased ROS (reactive oxygen species) levels,
reflecting mitochondrial dysfunction and cell toxicity [52]. As pre-
incubation with AG18051 was capable of preventing the toxicity
induced by Ab42, we pre-treated SH-SY5Y cells with AG18051
and exposed them then to Ab42. Interestingly, cells pre-treated
with 0.05–0.1 mM AG18051 were effectively protected from any
Ab42-induced ROS production, attaining levels comparable to
vehicle treatment (Fig. 7). This suggests that AG18051 may
prevent cell toxicity induced by Ab42 in part by preventing the
generation of ROS. In addition, the results also suggest that
ABAD dysfunction may be upstream of ROS production since
AG18051 can prevent ROS generation. Alternatively, AG18051
may trigger high estradiol levels, thereby counteracting ROS.
AG18051 only partially protects against reductions in cell
viability and estradiol levels in SH-SY5Y cells when
deregulated by human amylin (HA)
Previously, we had found that Ab42 and HA share toxicity
pathways via deregulation of mitochondrial proteins [52].
However, as shown above, Ab42 binds to and down-regulates
ABAD activity, while HA fails to do so (Fig. 1). We nonetheless
sought to determine whether AG18051 would have an effect in the
toxicity assays used above to measure Ab toxicity. We found that
HA induced an increase in LDH levels revealing its toxicity
(Fig. 8A), and a corresponding decrease in MTT absorbance
revealing its effect on metabolic functions (Fig. 8B). Co-incubation
of AG18051 with HA significantly prevented the increase in LDH
levels when compared with HA alone, but did not fully maintain
LDH to the levels of vehicle treatment indicating only a partial
protection from HA-induced toxicity (Fig. 8A). Co-incubation of
AG18051 with HA did not have any significant impact on MTT
levels (Fig. 8B).
AG18051 prevents the increase in ROS levels caused by
Ab42 and HA
Increased ROS levels have not only been implicated in AD but
also T2DM [50,51]. We had previously found that ROS levels in
SH-SY5Y cells are significantly increased upon exposure to either
Ab42 or HA [52]. To determine if the limited protective effect
seen by AG18051 on HA-induced toxicity may be due to an
inhibition of ROS generation, we pre-incubated SH-SY5Y cells
with AG18051 and then exposed them to HA. Similar to Ab42
(Fig. 7), pre-treatment with 0.05 mM AG18051 completely
prevented ROS generation by 0.5 mM HA (Fig. 9). Taken
together with the ROS data obtained for Ab42 (Fig. 7), this
suggests that AG18051 may be neuroprotective by preventing
ROS generation induced by either Ab42 or HA.
Discussion
Mitochondrial dysfunction has been recognized as a prominent,
early event in AD, but the underlying mechanisms are only partly
understood [53]. As a mediator of Ab toxicity in AD, a role has
been proposed for the mitochondrial protein ABAD, with
evidence for a direct interaction of Ab and ABAD [17]. Whether
in the AD brain, intracellular Ab - either in mitochondria or in the
cytoplasm - is present at sufficiently high quantities to have a
decisive role in disease is a matter to debate that has been revived
by the recent analysis of Ab plaque-forming 3xTg-AD using a
panel of Ab- and APP-specific antibodies [54]. Our current study
however adds to the body of data revealing a role for ABAD in
mediating Ab, irrespective of its mode of interaction.
By using the novel compound inhibitor of ABAD, AG18051 [41],
we revealed that Ab-mediated toxicity, metabolic impairment and
Figure 6. High-resolution respirometry revealed a reduction of oxygen consumption in Ab42-treated cells that was restored after
pre-treatment with AG18051. O2 flux and consumption by vital cells was measured after addition of different agents: pyruvate/glutamate, ADP,
FCCP, rotenone. Two-way ANOVA revealed a significant difference between the cellular respiration of the cells treated either with vehicle, Ab42 or
AG18051 alone, or AG18051 plus Ab42 (p,0.0001) (see scheme Fig. 3A). The respiratory rates of mitochondria were significantly reduced in Ab42-
treated cells compared to control (vehicle treated) cells and cells pre-treated with AG18051 (24 h) before exposure to Ab42. Values represent the
means 6 S.E. from n = 3–5 independent measurements. Post-hoc Bonferroni’s Multiple Comparison Test analysis for single experimental respiratory
conditions: *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0028887.g006
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reductions in estradiol levels could be abrogated. However different
from Ab, the inhibitor only partially restored the toxicity of HA, that
shares with Ab its amyloidogenic properties, and it had no effect at
all on the impaired metabolic activities or the reduced estradiol
levels caused by HA. The compound though abolished both the
Ab42- and HA-induced increases in ROS levels. These effects may
or may not require a direct interaction of Ab and ABAD. Provided
that Ab enters mitochondria and binds ABAD, it is believed to gain
access to the mitochondrial matrix via intracellular trafficking. Our
pull-down experiments using a biotinylated preparation of Ab
reveal that this peptide binds to ABAD in a lysate, while in contrast,
HA does not.
One of the established functions of ABAD is to convert in an
equilibrium reaction estrone to estradiol, a known anti-oxidant in
neuronal survival [31–33,55]. Additional substrates are known for
ABAD, such as the mitochondrial 2-methyl-3-hydroxybutyryl-
CoA [40,56].
ABAD is up-regulated in AD brain areas affected by Ab
pathology such as the cortex and hippocampus, as well as in Ab-
producing mouse models [17,23,26,57]. In neuroblastoma cells,
the cytotoxic effects of Ab are enhanced by ABAD over-
expression, and blocked with anti-ABAD antibodies [58].
Moreover, synthetic Ab fragments have been shown to bind and
inhibit ABAD in vitro [39]. As cells expressing catalytically inactive
mutants of ABAD failed to show an enhanced sensitivity to Ab, it
has been suggested that it is the enzymatic activity that is required
for mediating Ab toxicity [38]. In vivo, ABAD over-expression
potentiates the toxic effects of Ab, and obliteration of Ab-ABAD
complexes restores cell viability and memory deficits in transgenic
mice [17,26]. This inhibition was achieved using a truncated
version of ABAD as a decoy peptide (ABADDP) [17,26]. The
authors of the study concluded that segregating ABAD from Ab
protects both mitochondria and neurons from Ab toxicity by
restoring ABAD’s physiological functions.
Rather than employing a decoy peptide, we decided to use the
small compound, AG18051, a novel ABAD inhibitor to investigate
its putative protective effects. We performed co- and pre-
incubation experiments to determine whether the restoration of
estradiol levels by AG18051 is due to a direct inhibition of the
Ab42-ABAD interaction, or an indirect mechanism. By determin-
ing estradiol levels as a functional read-out of ABAD activity, we
found that exposure to Ab42 significantly decreased estradiol
levels (Fig. 3B, C). We have been using SH-SY5Y cells, a well-
established neuroblastoma cell line [43], to determine the effects of
AG18051 on ABAD. We found that pre-treatment of SH-SY5Y
cells with AG18051 before Ab42 exposure (Fig. 5C) was sufficient
to prevent the decrease in cell viability. This suggests that
AG18051 is capable of blocking Ab42 toxicity, possibly in part
by directly binding to ABAD and preventing the Ab42 toxicity
mediated by ABAD.
To determine whether these changes are due to ABAD
specifically, we performed co-incubation treatments of a novel
ABAD inhibitor, AG18051, with Ab42. We found that AG18051
effectively obliterated the toxic effects of Ab42 as demonstrated by
the restoration of LDH release and MTT absorbance to levels
indistinguishable from the vehicle control. Furthermore, AG18051
restored estradiol levels upon down-regulation by Ab42. This
effect is seen both in the cell lysate and the medium (data not
shown), suggesting that Ab42 exerts its toxicity by interfering with
intracellular levels of estradiol while also decreasing its secretion
Figure 7. AG18051 pre-treatment prevents ROS generation
induced by Ab. Ab causes reduced cellular (DCF) as well as
mitochondrial ROS (DHR), e.g. reduced mitochondrial superoxide anion
radicals (DHE). Levels are restored to vehicle upon pre-treatment with
AG18051, irrespective of whether the SH-SY5Y cells have been
incubated with Ab or HA. *, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0028887.g007
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into the extracellular environment. Our data indicate that Ab42-
induced toxicity is mediated by ABAD in part via the deregulation
of estradiol, which may contribute to cell toxicity.
To determine whether the change in estradiol levels is due to a
direct blockage of Ab42 by ABAD, we performed a pull-down
using biotinylated Ab42 in the presence of AG18051 (Fig. 4). We
found that AG18051 significantly decreased ABAD binding to
biotinylated Ab42, suggesting that AG18051 may be neuropro-
tective, in part by disrupting the physical interaction of ABAD
with Ab42. However, as binding was not completely abolished,
our results suggest that AG18051 may also act indirectly to
prevent cell toxicity. This is supported by the fact that AG18051 is
capable of preventing ROS production by HA (Fig. 9) even though
HA does not seem to bind to ABAD (Fig. 1B).
To unravel the effects of Ab42 and the involvement of ABAD
on the mitochondrial respiratory capacity, we performed whole
cell recording of total cellular respiration in SH-SY5Y cells
(Fig. 6). Consistent with previous findings investigating the effect
of a stable APP over-expression in SH-SY5Y cells gaining a
chronic overproduction of Ab within the low nanomolar range
[49], we observed a comparable impairment of oxygen con-
sumption rates in cells treated with Ab42 species for 5 days. Of
note, we present for the first time clear evidence that pre-
treatment with AG18051 prevented SH-SY5Y cells from a
decline in metabolic energy pathways induced by Ab42. The
capacity of mitochondria to re-phosphorylate ADP in state 3 is
dependent on the degree of coupling. Thus, pre-treatment with
AG18051 prevented the ETC (electronic transport chain) from
Ab42 toxicity and rescued the coupling state of mitochondria.
Importantly, the comparison of the mitochondrial energetic
capacity in cells treated with vehicle or AG18051 revealed a
similar bioenergetic homeostasis indicating that the inhibitor,
by itself, had no significant effect on respiration. These results
corroborate our findings demonstrating an AG18051-induced
Figure 8. The ABAD inhibitor AG18051 partially prevents the toxicity of HA, but not its metabolic impairment. (A) Co-incubation of HA
with AG18051 partially maintains levels of LDH release in SH-SY5Y cells suggesting that the toxicity of HA is partially mediated by ABAD. (B)
Treatment with 0.5 mM HA significantly decreases metabolic activity as shown with the MTT assay, which is not prevented with co-incubation with
AG18051. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0028887.g008
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prevention of ROS formation caused by Ab42, which in turn
impairs mitochondrial function.
That a defective or insufficient mitochondrial function might
play a potentially pathogenic role in another epidemic disease,
Type 2 diabetes mellitus (T2DM), has emerged in recent years
[59,60]. The association of diabetes with obesity and inactivity
indicates an important, and potentially pathogenic, link between
fuel and energy homeostasis and the emergence of metabolic
disease. Given the central role for mitochondria in fuel utilization
and energy production, mitochondrial dysfunction at the cellular
level can impact whole-body metabolic homeostasis [61]. T2DM
is characterized by HA deposition in the pancreas, and AD by Ab
deposition in the brain [59]. Ab and HA share a common b-sheet
secondary structure, a strong determinant in toxicity [62,63].
Supporting this notion we have shown previously that Ab and HA
share a mitochondrial toxicity profile [52]. In the present study we
found that HA caused toxicity and impaired metabolic functions.
When we co-incubated HA with AG18051 using the same
conditions as for Ab42, AG18051 significantly decreased levels of
LDH compared to just HA alone, suggesting that HA toxicity is in
part mediated by ABAD (Fig. 8A). Interestingly, co-incubation of
AG18051 with HA did not significantly change levels of MTT
absorbance, an established assay of mitochondrial function
(Fig. 8B) [64]. We have previously shown that to mitochondria,
at equimolar concentration, HA is more toxic than Ab42 [52].
This suggests that a higher concentration of AG18051 may be
required to restore the HA-induced mitochondrial toxicity.
Interestingly, while the MTT assay is a reliable test for metabolic
impairment, it does not always precisely reflect neuroprotective
effects, suggesting that the LDH assay is more accurate in
determining neurotoxicity [65]. It is therefore possible that the
neuroprotective effects of AG18051 against HA treatment differs
from that of Ab42. By extrapolation, this also means that HA and
Ab42 may exert a differential toxicity on ABAD. This is a
possibility, as exposure to HA did not alter estradiol levels, differ-
ent from Ab42 (Fig. 1A).
Pre-treatment of SH-SY5Y cells with AG18051 prevented both
the cellular and mitochondrial ROS formation induced by Ab42
and HA suggesting that ABAD is involved in their mechanism of
toxicity. We have shown previously that increased ROS
generation and reduced mitochondrial complex IV activity was
the common mechanism of toxicity of HA and Ab42 [52]. This is
in agreement, in the case of Ab, with other reports showing that
Ab results in ROS generation and reduction of complex IV in AD
mouse models and that there is a direct involvement of ABAD in
these processes [17,66,67]. Now it appears that HA ROS gener-
ation is also mediated by ABAD. However, while AG18051 may
be protecting against most of the toxic effects of Ab42, it does so
only partially for HA. This indicates that HA may have additional
toxicity pathways unrelated to ROS generation or ABAD.
The mechanism of protection by AG18051 is probably through
its inactivation of ABAD’s catalytic activity. Inactive mutants of
ABAD do not enhance the toxicity of Ab that is observed when
wildtype ABAD is over-expressed, despite the fact that Ab still
binds to the mutant ABAD with the same affinity as wild-type
[68]. It has also been reported that siRNA-ABAD and the
subsequent reduction of ABAD expression prevents the toxic
effects of Ab in SH-SY5Y cells induced to over-express ABAD by
corticosterone and Ab [67]. But why would the catalytic activity of
ABAD be harmful when Ab is bound to it? In view of the
participation of ABAD in mitochondrial RNAse P, which is
responsible for the centrally important processing of the
mitochondrial ETC mRNA [37], one possibility is that ABAD’s
primary function is as an RNAse P and that Ab and HA induce a
toxic gain of function related to its catalytic activity compromising
its RNAse P function. This would result in aberrant processing of
the ETC mRNA, a dysfunctional ETC and ROS generation. Ab
may do this directly by binding to ABAD and, while there is no
Figure 9. AG18051 pre-treatment prevents ROS generation
also induced by HA. As for Ab, HA causes reduced cellular (A) as well
as mitochondrial ROS (B), e.g. reduced mitochondrial superoxide anion
radicals (C). Levels are restored to vehicle upon pre-treatment with
AG18051. *, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0028887.g009
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evidence that HA directly interacts with ABAD, our study shows
that ABAD is nevertheless key to the toxicity of HA.
In conclusion, we extend previous findings on the role of
mitochondria, and in particular the mitochondrial enzyme ABAD,
in mediating Ab42 toxicity. We established a neuroprotective
effect of AG18051, a novel ABAD-specific inhibitor, and showed
that it promotes cell survival in part by preventing the generation
of ROS and stabilizing estradiol levels. Our findings extend
previous studies suggesting ABAD activity as a suitable biomarker
for impaired brain functions. We further present AG18051 and
related compounds for consideration in therapeutic strategies
targeting AD.
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